Search

Crinetics Pharmaceuticals Inc

Suletud

SektorTervishoid

84.43 -0.05

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

84.4

Max

84.7

Põhinäitajad

By Trading Economics

Sissetulek

7M

-121M

Müük

14M

25M

Aktsiakasum

-1.14

Kasumimarginaal

-481.149

Töötajad

594

EBITDA

-4.7M

-131M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+1.3% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. nov 2026

Turustatistika

By TradingEconomics

Turukapital

63M

8.9B

Eelmine avamishind

84.48

Eelmine sulgemishind

84.43

Uudiste sentiment

By Acuity

60%

40%

292 / 340 Pingereas Healthcare

Crinetics Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. aug 2026, 23:56 UTC

News

Molson Coors Beverage Co shares advanced in after-market hours to $43.20, following Q2 revenues of $3.10 billion that met analyst expectations.

13. aug 2026, 23:56 UTC

News
Event

Bristol-Myers Squibb's shares are lower after FDA approval of ZENBEXUS for multiple myeloma, amid concerns over drug risks and ongoing trial verification.

13. aug 2026, 23:51 UTC

News

Milestone Scientific reported second-quarter sales of $2.841 million, exceeding estimates. Shares are higher in after-market hours following the earnings announcement.

13. aug 2026, 23:51 UTC

News
Social Media

Campbell Soup Co filed for a mixed securities shelf to raise capital. Shares are higher in after-market trading amid positive social media sentiment.

13. aug 2026, 23:51 UTC

News
Social Media

Charter Communications received final approval for its Cox acquisition, but shares are trading lower in after-market hours, reflecting downward pressure since Thursday's close.

13. aug 2026, 23:46 UTC

News

Citi analyst Ronald Josey raised Wayfair's price target to $133.00 from $95.00, maintaining a Buy rating. Shares are trading higher in after-market hours.

13. aug 2026, 23:46 UTC

News
Correlated Moves

Synchrony Financial shares declined in after-market hours following the appointment of Nimrod Barak as Chief AI Officer, effective June 30, 2026.

13. aug 2026, 23:46 UTC

News

UWM Holdings Corp secures $2.05 billion investment from Oaktree and SFS Group. Shares are trading higher in after-market hours following the announcement.

13. aug 2026, 23:41 UTC

News

EPR Properties declared a monthly cash dividend of $0.31 per share, payable September 15, 2026, as shares moved higher during after-market hours.

13. aug 2026, 23:41 UTC

News

Credicorp Ltd reported second-quarter earnings of $7.29 per share, exceeding estimates. The stock moved higher during after-market hours following this performance.

13. aug 2026, 23:41 UTC

Social Media
News

Eton Pharmaceuticals reported record revenue of $37.6 million and raised its full-year guidance to over $145 million, driving shares higher in after-market trading.

13. aug 2026, 23:41 UTC

News

Norway's sovereign wealth fund increased its Bitcoin exposure through MicroStrategy investments. Bitcoin is trading lower today, remaining below its 20-day moving average.

13. aug 2026, 23:36 UTC

News

Lucid Group Inc introduced the Lucid Gravity GT-S SUV priced at $125,900, but shares declined in after-market trading following the announcement.

13. aug 2026, 23:31 UTC

News

Western Union shares rise in after-market trading following New York Governor Kathy Hochul's approval of its acquisition of International Money Express.

13. aug 2026, 23:31 UTC

Correlated Moves
News
Social Media

Microsoft shares are trading lower after a report on OpenAI's $40 billion revenue run rate and Iren's $9.7 billion cloud services contract.

13. aug 2026, 23:31 UTC

Social Media
News

Micron Technology launches a $250 million AI-focused fund, raising total commitments to $550 million. Shares are trading higher in after-market hours.

13. aug 2026, 23:31 UTC

News
Social Media

Nu Holdings Ltd shares rose in after-market trading following strong Q2 results, with revenue of $5.9 billion surpassing estimates and net profit reaching $1.06 billion.

13. aug 2026, 23:26 UTC

News

CoreCivic Inc shares rose in after-market trading following positive analyst ratings updates and a raised price target from Benchmark Co. to $45.00.

13. aug 2026, 23:26 UTC

Correlated Moves
News

Diodes Inc announced a $325 million private placement of convertible senior notes due 2031. Shares are lower in after-market trading amid broader market trends.

13. aug 2026, 23:26 UTC

News

Hewlett Packard Enterprise shares rose in after-market trading, buoyed by positive sentiment from Cisco's earnings and broader market gains.

13. aug 2026, 23:21 UTC

News

Knight-Swift Transportation affirms quarterly cash dividend of $0.20 per share, though shares are trading lower in after-market hours.

13. aug 2026, 23:21 UTC

News

Rapid7 Inc shares rose in after-market trading after reporting adjusted EPS of $0.44, exceeding expectations, and raising full-year guidance to $1.81.

13. aug 2026, 23:16 UTC

News
Correlated Moves

Citigroup's U.S. Consumer Cards business will acquire Kard Financial to enhance credit card rewards for its 70 million cardmembers. Shares are little changed in after-market trading.

13. aug 2026, 23:16 UTC

Correlated Moves
News

Sunrun Inc. shares declined in after-market trading, reflecting broader market trends. Recent financial results showed sales of $543.73 million and revenue of $869.99 million.

13. aug 2026, 23:16 UTC

News

Jack in the Box Inc shares rose in after-market trading following UBS and Citigroup raising their price targets to $20, indicating a stable outlook.

13. aug 2026, 23:11 UTC

News

Sabre Corp reported second-quarter revenue of $712 million and raised its full-year profitability outlook, though shares are trading lower in after-market hours.

13. aug 2026, 23:06 UTC

Social Media
News

Tesla shares gained in after-market hours following the end of a lengthy strike by IF Metall and as Michael Burry covered his short position.

13. aug 2026, 23:06 UTC

News

Silicon Motion Technology closed a $1.15 billion offering of Convertible Senior Notes due 2031, with shares trading higher in after-market hours.

13. aug 2026, 23:06 UTC

News
Event

Target Corp will announce Q2 FY2026 earnings on August 19, with an estimated EPS of $2.24 and revenue of $25.7 billion. Shares showed little change after hours.

13. aug 2026, 23:02 UTC

Social Media
News

Cboe Global Markets announced a dividend increase to $0.86 per share, effective September 15, 2026. Shares are trading higher in after-market hours.

Võrdlus sarnastega

Hinnamuutus

Crinetics Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

1.3% tõus

12 kuu keskmine prognoos

Keskmine 85.56 USD  1.3%

Kõrge 95 USD

Madal 80 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Crinetics Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

14 ratings

2

Osta

12

Hoia

0

Müü

Sentiment

By Acuity

292 / 340 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat